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Leishmaniasis, a zoonosis caused by Leishmania parasites, 
is an ancient disease that has recently been classified as an emerging 
pathology worldwide. This neglected disease has turned into a public 
health problem since environmental changes and other factors are 
favouring its expansion; there is also concern about treatment failure 
and emerging resistance to antileishmanial drugs [1,2].  
Phlebotominae sand flies are the biological vectors of this 
protozoal disease. Although small forest rodents have been 
considered the main reservoir for the parasites, there is concern 
about domestic dog becoming an important reservoir for human 
visceral leishmaniasis caused by L. infantum; urbanization, 
deforestation and inadequate vector control contribute to this 
threaten. The number of infected dogs in South America is estimated 
in millions, rates of infection are particularly high in Venezuela and 
Brazil. In recent years the disease showed an increasing spreading 
tendency to the South of the continent involving countries like 
Paraguay and Argentina [3,4]. There is some evidence that a high 
prevalence of canine infection is associated with high risk of human 
disease in this region, where a number of Leishmania species have 
been isolated from dogs. In most cases canine leishmaniosis (CanL) is 
caused by L. infantum (syn. L. chagasi) and L. braziliensis. In 
neotropical regions of South America canine tegumentary 
leishmaniosis, a clinical form with single cutaneous or mucosal 
lesions, is in general associated with L. braziliensis infection, although 
other species have also been reported [5,6] CanL is characterized by 
a long asymptomatic incubation period after which dogs may remain 
asymptomatic, develop a mild illness or a symptomatic disease. 
Diffuse alopecia, dry seborrhea with silverwhite,  skin scaling, ulcers 
in footpads and ears, eczema in nose or ears,  mucosal ulcers, poor 
body condition and lymphadenopathy are some of the main signs. 
However, lymphadenomegaly, exfoliative dermatitis and weight loss 
appear as the most relevant signs of CanL on which veterinarians 
based their suspicion of infection. [7,8] 
Several drugs are used for the therapy of CanL, however in 
most cases treatments do not eliminate the infection but they are 
able to relieve clinical signs. Most treated animals cure clinically but 
they might relapse. Combined therapy, usually allopurinol and 
meglumine antimoniate or miltefosine is needed for dogs that do not 
respond well to first-line medicine.   Other treatments include 
Amphotericin B, pentamidine, aminosidine (paramomycin), 
ketoconazole, and metronidazole with spiramycin or with 
enrofloxacin. Effectiveness of second line drugs still needs 
investigation [9,10] 
Fluconazole (FLZ) is an antifungal that reaches high 
concentration in the skin due to great affinity to keratin in the 
stratum corneum. However, the use of FLZ as topical treatment is not 
a clinical practice [11,12].  Since FLZ inhibits the production of 
ergosterol, the main sterol in membranes of fungi and parasites, oral 
FLZ has been reported for the treatment of human cutaneous 
leishmaniasis caused by L. major [13-15]. FLZ has been used in 
veterinary practice for canine nasal aspergillosis/penicilliosis and 
Cryptococcosis [16,17]  
Herein we report a case of CanL in one dog with resistant 
tegumentary lesions treated with combined therapy of oral 
allopurinol and FLZ- ME applied topically. Microemulsions (ME) have 
outstanding properties for topical application and better FLZ 
penetration and retention within the skin was observed when 
comparing a ME with other topical vehicles such as creams or gels. 
[18] In vitro assay with FLZ-ME showed inhibitory activity against L 
braziliensis promastigotes. [19] 
Abstract 
Canine leishmaniosis (CanL) is a zoonosis mainly caused by Leishmania 
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2. Case Report 
A mongrel six-year-old female dog (weight 8 kg), was 
admitted in a veterinary clinic (“Veterinaria del Oeste”; city of 
Posadas, Misiones, Argentina) with regular general condition. 
Physical examination revealed deteriorated body condition, 
lymphadenopathy and multiple ulcerated lesions in nasal and ocular 
regions, and the forelimbs (Table 1a; Figure 1a, b). 
 
 
Figure 1: a,b lesions before local treatment; c,d after first course of combined treatment with local fluconazole 
 
Table 1: Lesion localization and description 
No. of 
lesion 
Localization a- Before the application of local 
treatment 
b- After 3 weeks of combined   
treatment 
Size (cm) Type of lesion OI Size (cm) Type of lesion OI 
1 Dorsum of nose 3 Ulcer  No 1  Hyperkeratosis No 
2 Dorsum left carpal región 1 Crusted wound yes 1         Crusted No 
3 Dorsum left metacarpian medial región 0.5 Crusted wound yes --- Crusted No 
4 Side of right eye 0.5 Ulcer No 0,5  Crusted No 
5 Side of left eye 1 Crusted wound yes --- Hyperkeratosis No 
OI: overinfection; --- no lesion  
 
Cytological examination was made on samples taken by 
fine needle aspiration of popliteal lymph nodes and cutaneous 
lesions. Samples were stained with a rapid stain technique (Tinción 
15, Biopur Diagnostics) and were observed at 100x ( by immersión) 
with optic microscope (Wesco Bio VU 2300).  Lymph node revealed 
heterogeneous cell population, naked nuclei, small and medium 
lymphocytes, lymphoblasts, some mitotic figures, polymorphonuclear 
neutrophils (PMN) and eosinophils, mononuclear macrophages (MN) 
and plasma cells.  Free bacteria and free microorganisms round to 
oval, with a core and basophils kinetoplast compatible with 
Leishmania sp. amastigotes. Cutaneous lesions curettage revealed 
hemorrhagic background, sheets and strands of keratin, isolated 
squamous epithelial cells, PMN and eosinophils in varying degrees of 
degeneration, MN lymphocytes and free bacteria. Presence of free 
amastigotes of Leishmania sp. and  basophils yeast microorganisms 
compatible with Malassezia sp. were also observed. 
Serological evaluation with an immunocromatographic 
method based in the detection of specific antibodys against rk 39 
antigen was made (Kalazar Detect,Lab.In Bios) and Leishmania 
infantum was confirmed as the  etiologic agent. 
The diagnostic was visceral leishmaniosis with 
lymphadenitis, presence of reactive lymph node and overinfection 
with malassezia. The dog was initially prescribed allopurinol 75 mg 
twice a day and after two weeks of treatment a FLZ-ME was added 
twice a day topically over the lesions. Topical formulation was 
prepared according to composition selected and discussed in a 
previous work. [18] 
After 3 weeks of combined treatment some of the lesions 
disappeared or reduced and ulcers were healed (Table 1b; Figure 
1c,d) No adverse effects were observed. Local treatment was 
suspended after 6 weeks. After two years of initial cure of ulcers, a 
little relapse was observed despite the maintenance of systemic 
administration of Allopurinol. Local treatment was applied again and 
after 5 weeks lesions were healed (Figure 2).  
 
Figure 2: Dog after the second year follow-up and second 
treatment with local FLZ microemulsion 
 
International ethical standards were considered and 
Approval has been obtained from the Ethical Committee of the 
Faculty of Pharmacy and Biochemistry, University of Buenos Aires 
(050313-2 EXP-FYB 0747495/2012 and 170511-1)                                                                                                                                                                  
 
3. Discussion 
In the case presented the dog had an early amelioration of 
systemic manifestations such as lymphadenomegaly and biochemical 
alterations, but cutaneous lesions needed a more intensive treatment. 
We observed that concomitant use of topical FLZ gave additional 
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support for the cure of lesions and diminished disease progression. 
The clinical cure reported herein is relevant as topical therapy lead 
drug to the target site with less adverse effects.  Combined therapy in 
the case of dogs would enable a better control of resistant cutaneous 
manifestations found in many clinical cases and it might also reduce 
the need for systemic therapy. This last fact is encouraging 
considering that pentavalent antimonials and miltefosine are not 
always available for use in dogs and as mentioned allopurinol is not 
completely effective for the control of some lesions. Moreover it is 
important to consider the emerging resistance to pentavalent 
antimonials and there is also evidence of low sensitivity to these 
drugs in the case of dogs.  A key point is that CanL is not a 
homogenous disease; a wide spectrum of clinical manifestations and 
different degrees of severity can occur, so it is essential to consider a 
different therapeutic approach for each clinical stage. [20] 
Early treatment of cutaneous lesions might help to prevent 
disease progression.  Also, topical FLZ therapy is useful to avoid co-
infections with Malassezia spp. very common in dogs. Topical 
treatments help therapy compliance which is a major issue since it is 
critical that infected dogs receive treatment to reduce parasite load. 
This case is encouraging; further work and experience with more 
animals is needed to assess the efficacy of FLZ for the local treatment 
of CanL.  
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